Foundation Medicine Positions Blood-Based TMB Test as Companion Dx to First-Line Immunotherapy

Sep 12, 2017

|

Premium

NEW YORK (GenomeWeb) – Foundation Medicine said last week that it is advancing a blood-based version of its tumor mutational burden test as a companion diagnostic to Roche/Genentech’s immunotherapy drug Tecentriq (atezolizumab) in first-line treatment of non-small cell lung cancer patients.

The assay is moving forward in two clinical trials. In a single-arm trial called B-F1RST, investigators are retrospectively analyzing blood-based TMB status in NSCLC patients treated with first-line Tecentriq regardless of their biomarker status.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Recent Headlines from
Precision Oncology News

The Scan

Diversity of African Genomes

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

'We Gotta Change These Numbers'

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Science Like a Girl

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

Science Looks at Beneficial Genetic Variants in the Melanesian Population, and More

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.

Featured White Papers

Developmental Validation of the MiSeq FGx System

A Comprehensive MPS Workflow For Severely Degraded Nuclear DNA

Modern DNA Forensic Testing Capabilities

MiSeq FGx Reagent Micro Kit tech note

Oct

21

Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genomics is a key element in the potential of precision medicine to transform oncology.

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov

04

Featured Webinar

Digital Solutions for NGS Genotyping – Accuracy, Clinical Relevancy, and Report Generation

This webinar will provide a look at how the Institute of Hematopathology in Hamburg, Germany, is implementing complex genomic testing for lung cancer.

Menu